Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
about
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparisonAdverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendationBaseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety studyPostinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection.A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.Olanzapine pamoate for the treatment of schizophrenia.Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?A review of olanzapine pamoate.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study.Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being.Is Low Body Mass Index a Risk Factor for Postinjection Delirium/Sedation Syndrome?Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.Olanzapine long-acting injection: insights from an early case series in the UK.Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.Understanding depot antipsychotics: an illustrated guide to kinetics.Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.Postinjection delirium/sedation syndrome with long-acting olanzapine pamoate in a middle-aged female.
P2860
Q33600247-8DCA9F21-5D58-41C2-A4E7-A3CDA73D5530Q34286350-B045FDA5-06CD-4CA6-A240-85CF4B3CFF18Q34293855-1F84565B-F7E3-4E9D-91E7-1131E6EDBE8FQ34293899-C59CBC98-47DE-46FF-A27C-0BE55D2255CCQ34315836-A62CCC13-3854-4B02-AE5D-31703916B96DQ34720828-041770F7-4962-4848-91B2-65629320F31EQ34775426-6BDC017B-9D1A-46B2-9167-F365326E5899Q35321641-44E9ED35-84D6-4131-B159-3AA38207F9EFQ35683860-FC097566-71FA-4EF6-8C86-74E3F17986C3Q35841195-A9615D71-7702-43AB-B454-9F9ED3B9F23FQ37167256-F645FAF5-FA83-4316-9A0B-7D453B7B412AQ37501165-1F2BC6D3-60E4-476A-A243-817666258EECQ37831310-C1A163BF-83E2-4A65-8BDD-3A6FD1A73D97Q37886136-D79BF422-530A-42EB-842D-0130697FCD43Q38022638-9BF7173D-446C-4FC0-8665-37D8474BF90AQ38115487-BAC139CA-BD83-4199-9CDE-3692F205455BQ38125213-A7B458AE-92FA-498F-BCCE-AA3FF566666DQ38271353-84D66177-BFAB-4D76-8CFE-34EF0C73EB1DQ38622801-E9C4E821-0A22-48B9-B629-1A8862A014BAQ38694855-9237EE11-219C-4094-B2F4-A5C2109F4E04Q39207081-48A994B5-3DD8-4540-B8E1-D2F2BE6D89AFQ42128867-D93C09AD-970F-47FE-9E04-2EDE77379CCFQ42520005-D79D7A8A-6C47-470E-898F-EA6BE6DBE67EQ42544159-09CD5F64-7854-4A19-852F-0EC650B9B356Q43952283-88655091-3BF1-4695-BD57-B03292BE4B8DQ45769368-582D5128-252A-4149-ACD7-0A190906BCD2Q54217848-904EFC18-6BAB-4E3D-BF60-0D1DFE3638F4Q54942218-125F91CF-0437-4AFC-A526-3178D90EAAB8
P2860
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Post-injection delirium/sedati ...... : investigations of mechanism.
@ast
Post-injection delirium/sedati ...... : investigations of mechanism.
@en
type
label
Post-injection delirium/sedati ...... : investigations of mechanism.
@ast
Post-injection delirium/sedati ...... : investigations of mechanism.
@en
prefLabel
Post-injection delirium/sedati ...... : investigations of mechanism.
@ast
Post-injection delirium/sedati ...... : investigations of mechanism.
@en
P2093
P2860
P356
P1433
P1476
Post-injection delirium/sedati ...... : investigations of mechanism.
@en
P2093
David P McDonnell
Holland C Detke
Jason Johnson
Malcolm I Mitchell
Mary Stickelmeyer
Prajakti Kothare
Richard F Bergstrom
Sebastian Sorsaburu
P2860
P2888
P356
10.1186/1471-244X-10-45
P577
2010-06-10T00:00:00Z
P6179
1046501525